These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35719821)

  • 1. The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life.
    Tarabzuni O
    Cureus; 2022 May; 14(5):e25045. PubMed ID: 35719821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu F; Feng C; Shen H; Fu H; Mao J
    Kidney Dis (Basel); 2021 Sep; 7(5):343-349. PubMed ID: 34604341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
    Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan.
    Gkekas E; Tang TYT; Green A; Davidson H; Fraser R; Sayer JA; Srivastava S
    Front Nephrol; 2022; 2():984165. PubMed ID: 37674994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study.
    Lai S; Mangiulli M; Perrotta AM; Gigante A; Napoleoni L; Cipolloni E; Mitterhofer AP; Gasperini ML; Muscaritoli M; Cianci R; Giovannetti A; Falco F; Mastroluca D; Mazzaferro S
    Curr Vasc Pharmacol; 2021; 19(5):556-564. PubMed ID: 32957887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
    Akihisa T; Kataoka H; Makabe S; Manabe S; Yoshida R; Ushio Y; Sato M; Tsuchiya K; Mochizuki T; Nitta K
    Clin Exp Nephrol; 2022 Jun; 26(6):540-551. PubMed ID: 35165806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
    BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study.
    Masuda H; Shimizu N; Sekine K; Okato A; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    In Vivo; 2023; 37(2):801-805. PubMed ID: 36881088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.